growth factor receptors


Summary: Cell surface receptors that bind growth or trophic factors with high affinity, triggering intracellular responses which influence the growth, differentiation, or survival of cells.

Top Publications

  1. Sakisaka T, Ikeda W, Ogita H, Fujita N, Takai Y. The roles of nectins in cell adhesions: cooperation with other cell adhesion molecules and growth factor receptors. Curr Opin Cell Biol. 2007;19:593-602 pubmed
    ..Furthermore, nectin interacts in trans with nectin-like molecule-5 (Necl-5) and regulate cell movement and proliferation. We describe cooperative roles of nectins with other CAMs and growth factor receptors.
  2. Kampmeier J, Baldysiak Figiel A, de Jong Hesse Y, Lang G, Lang G. Effect of growth factors on proliferation and expression of growth factor receptors in a human lens epithelial cell line. J Cataract Refract Surg. 2006;32:510-4 pubmed
    ..Further investigation of growth factor-induced responses of both cell types will provide new insight into the proliferative processes involved in postoperative secondary cataract formation. ..
  3. Mazzone M, Comoglio P. The Met pathway: master switch and drug target in cancer progression. FASEB J. 2006;20:1611-21 pubmed
    ..As we suggest possible directions for drug development, we propose the receptor for the hepatocyte growth factor, Met, as an ideal target for tackling cancer progression. ..
  4. Jones M, Caswell P, Norman J. Endocytic recycling pathways: emerging regulators of cell migration. Curr Opin Cell Biol. 2006;18:549-57 pubmed
    ..In particular, detailed descriptions have emerged of the mechanisms that recruit integrins and growth factor receptors to Rab4- and Rab11-driven pathways...
  5. Bardelli C, Sala M, Cavallazzi U, Prat M. Agonist Met antibodies define the signalling threshold required for a full mitogenic and invasive program of Kaposi's Sarcoma cells. Biochem Biophys Res Commun. 2005;334:1172-9 pubmed
  6. Hopfner M, Schuppan D, Scherubl H. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol. 2008;14:1-14 pubmed
    ..Clinical trials indicate that growth factor receptors and their related signalling pathways play important roles in HCC cancer etiology and progression, thus ..
  7. Pike L. Growth factor receptors, lipid rafts and caveolae: an evolving story. Biochim Biophys Acta. 2005;1746:260-73 pubmed
    b>Growth factor receptors have been shown to be localized to lipid rafts and caveolae...
  8. Idbaih A, Ducray F, Sierra del Rio M, Hoang Xuan K, Delattre J. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors. Oncologist. 2008;13:978-92 pubmed publisher
    b>Growth factor receptors and angiogenesis play major roles in the oncogenesis of gliomas...
  9. Kong Beltran M, Seshagiri S, Zha J, Zhu W, Bhawe K, Mendoza N, et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res. 2006;66:283-9 pubmed

More Information


  1. Stommel J, Kimmelman A, Ying H, Nabioullin R, Ponugoti A, Wiedemeyer R, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 2007;318:287-90 pubmed
    ..Thus, effective GBM therapy may require combined regimens targeting multiple RTKs. ..
  2. Carapancea M, Alexandru O, Fetea A, Dragutescu L, Castro J, Georgescu A, et al. Growth factor receptors signaling in glioblastoma cells: therapeutic implications. J Neurooncol. 2009;92:137-47 pubmed publisher
    ..Our results showed that GB cells are in general resistant to treatment and illustrate the difficulties in predicting the treatment response in malignant gliomas. ..
  3. Holash J, Thurston G, Rudge J, Yancopoulos G, Adjei A, Bergers G, et al. Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents. Cancer Metastasis Rev. 2006;25:243-52 pubmed
  4. Margadant C, Frijns E, Wilhelmsen K, Sonnenberg A. Regulation of hemidesmosome disassembly by growth factor receptors. Curr Opin Cell Biol. 2008;20:589-96 pubmed publisher
    ..Here, we discuss recent advances that shed light on the residues involved, the identity of the kinases that phosphorylate them, and the interactions that become disrupted by these phosphorylations...
  5. D Andrea L, Del Gatto A, De Rosa L, Romanelli A, Pedone C. Peptides targeting angiogenesis related growth factor receptors. Curr Pharm Des. 2009;15:2414-29 pubmed
    ..Finally, we highlight the pharmacological and diagnostic applications of these peptides in angiogenesis related diseases. ..
  6. Lutterbach B, Zeng Q, Davis L, Hatch H, Hang G, Kohl N, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 2007;67:2081-8 pubmed
    ..These results strongly suggest that Met amplification identifies a subset of NSCLC likely to respond to new molecular therapies targeting Met. ..
  7. Streuli C, Akhtar N. Signal co-operation between integrins and other receptor systems. Biochem J. 2009;418:491-506 pubmed publisher
  8. Xu L, Hausmann M, Dietmaier W, Kellermeier S, Pesch T, Stieber Gunckel M, et al. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines. BMC Cancer. 2010;10:302 pubmed publisher
    Cholangiocarcinoma (CC) is a malignant neoplasm of the bile ducts or the gallbladder. Targeting of growth factor receptors showed therapeutic potential in palliative settings for many solid tumors...
  9. Boccaccio C, Comoglio P. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer. 2006;6:637-45 pubmed
  10. Hopfner M, Schuppan D, Scherubl H. Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives. World J Gastroenterol. 2008;14:2461-73 pubmed
    ..e. combining growth factor (receptor)-targeting agents with chemo- or biotherapeutics or with other novel anticancer drugs such as HDAC or proteasome inhibitors will be taken into account. ..
  11. Engelman J, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park J, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039-43 pubmed
    ..Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well. ..
  12. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 2008;68:9479-87 pubmed publisher
    ..Therefore, inhibition of HGF-MET signaling may be a considerable strategy for more successful treatment with gefitinib. ..
  13. Vigna E, Pacchiana G, Mazzone M, Chiriaco C, Fontani L, Basilico C, et al. "Active" cancer immunotherapy by anti-Met antibody gene transfer. Cancer Res. 2008;68:9176-83 pubmed publisher
    ..These data provide proof of concept both for targeting the Met receptor and for a gene transfer-based immunotherapy strategy. ..
  14. Smolen G, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A. 2006;103:2316-21 pubmed
    ..MET amplification may thus identify a subset of epithelial cancers that are uniquely sensitive to disruption of this pathway and define a patient group that is appropriate for clinical trials of targeted therapy using MET inhibitors. ..
  15. Ivaska J, Heino J. Interplay between cell adhesion and growth factor receptors: from the plasma membrane to the endosomes. Cell Tissue Res. 2010;339:111-20 pubmed publisher
    ..and, following ligand binding, can activate the same cellular signaling pathways that are regulated by growth factor receptors. Recent reports have indicated that the two receptor systems also collaborate in many other ways...
  16. Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, Mitsudomi T. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol. 2009;4:5-11 pubmed publisher
    ..About 5% of pulmonary adenocarcinomas in this cohort of Japanese patients were driven by activated MET by gene amplification or splice mutations. Such patients would be candidates for targeted therapy against MET. ..
  17. Pozner Moulis S, Pappas D, Rimm D. Met, the hepatocyte growth factor receptor, localizes to the nucleus in cells at low density. Cancer Res. 2006;66:7976-82 pubmed
    ..This work suggests processing of the Met receptor, analogous to ErbB4, resulting in the release of the cytoplasmic domain and its translocation to the nucleus in cells at low density. ..
  18. Oliva J, Griner E, Kazanietz M. PKC isozymes and diacylglycerol-regulated proteins as effectors of growth factor receptors. Growth Factors. 2005;23:245-52 pubmed
    ..One of the well-established effectors of growth factor receptors is protein kinase C (PKC), a family of serine-threonine kinases that have been known for years as the ..
  19. Tang Z, Du R, Jiang S, Wu C, Barkauskas D, Richey J, et al. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer. 2008;99:911-22 pubmed publisher
    ..Furthermore, optimised inhibition may be further achieved with MET inhibition in combination with erlotinib or an irreversible EGFR-TKI. ..
  20. Hofer E, Schweighofer B. Signal transduction induced in endothelial cells by growth factor receptors involved in angiogenesis. Thromb Haemost. 2007;97:355-63 pubmed these receptors operate in the context of additional signals transduced by non-endothelial specific growth factor receptors, inflammatory cytokine receptors as well as adhesion molecules...
  21. Ekman S, Bergqvist M, Heldin C, Lennartsson J. Activation of growth factor receptors in esophageal cancer--implications for therapy. Oncologist. 2007;12:1165-77 pubmed
    ..This review provides a summary of the role of growth factors and their receptors in esophageal cancer and discusses their potential roles as biomarkers and as targets in therapy. ..
  22. McIntyre E, Blackburn E, Brown P, Johnson C, Gullick W. The complete family of epidermal growth factor receptors and their ligands are co-ordinately expressed in breast cancer. Breast Cancer Res Treat. 2010;122:105-10 pubmed publisher
    ..Analysing the data using the Cox Proportional Hazards model showed that, in this dataset, the most powerful predictors of relapse free interval and overall survival were the combined measurement of only Epigen and Neuregulin 4. ..
  23. Krolewski J. Cytokine and growth factor receptors in the nucleus: what's up with that?. J Cell Biochem. 2005;95:478-87 pubmed
  24. Shinomiya N, Gao C, Xie Q, Gustafson M, Waters D, Zhang Y, et al. RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res. 2004;64:7962-70 pubmed
    ..Thus, Met small-interfering RNA adenoviruses are reliable tools for studying Met function and raise the possibility of their application for cancer therapy. ..
  25. Tran K, Griffith L, Wells A. Extracellular matrix signaling through growth factor receptors during wound healing. Wound Repair Regen. 2004;12:262-8 pubmed
    ..We provide a model framework for further studies into this emerging class of signals. ..
  26. Nguyen D, Schrump D. Growth factor receptors as targets for lung cancer therapy. Semin Thorac Cardiovasc Surg. 2004;16:3-12 pubmed
    Dysregulated signal transduction of growth factor receptors contributes to the process of malignant transformation by promoting cell proliferation, motility, and invasion through extracellular matrix as well as angiogenesis...
  27. Sanada F, Taniyama Y, Iekushi K, Azuma J, Okayama K, Kusunoki H, et al. Negative action of hepatocyte growth factor/c-Met system on angiotensin II signaling via ligand-dependent epithelial growth factor receptor degradation mechanism in vascular smooth muscle cells. Circ Res. 2009;105:667-75, 13 p following 675 pubmed publisher
    ..These data suggest that the HGF/c-Met system might regulate extrinsic factor signaling that maintains the homeostasis of organs. ..
  28. Sousa I, Clark T, Toma C, Kobayashi K, Choma M, Holt R, et al. MET and autism susceptibility: family and case-control studies. Eur J Hum Genet. 2009;17:749-58 pubmed publisher
    ..02). The previously reported positive association of rs1858830 failed to replicate in this study. Overall, our findings provide further evidence that MET may play a role in autism susceptibility. ..
  29. Kölble K. Morphological detection of hormone and growth factor receptors in breast cancer. Recent Results Cancer Res. 2007;176:201-9 pubmed
    ..None of the numerous molecular markers available has surpassed hormone and growth factor receptors in their relevance for the selection of targeted therapies...
  30. Gennigens C, Sautois B, Rorive A, Fillet G, Jerusalem G. [Current therapeutic progress in oncology: the development of targeted therapies]. Rev Med Liege. 2007;62:391-8 pubmed
    ..In particular, targeted therapies were developed against epithelial growth factor receptors and angiogenesis. We can expect specifise therapies against many other targets in the near future...
  31. Ghaneh P, Costello E, Neoptolemos J. Biology and management of pancreatic cancer. Gut. 2007;56:1134-52 pubmed
  32. Hernández D, Paris N, Neuhaus J, Deloche O. The yeast Saccharomyces cerevisiae is not an efficient tool for in vivo studies of plant vacuolar sorting receptors. Plant Cell. 2005;17:1339-42 pubmed
  33. Tolbert W, Daugherty Holtrop J, Gherardi E, Vande Woude G, Xu H. Structural basis for agonism and antagonism of hepatocyte growth factor. Proc Natl Acad Sci U S A. 2010;107:13264-9 pubmed publisher
    ..These results reveal the molecular determinants that regulate the agonist/antagonist properties of HGF NK2 and provide critical insights into the dimerization mechanism that regulates the Met receptor activation by HGF. ..
  34. Lazo P. Functional implications of tetraspanin proteins in cancer biology. Cancer Sci. 2007;98:1666-77 pubmed
    ..that organize other membrane proteins such as integrins, human leukocyte antigen (HLA) antigens and some growth factor receptors. Although most tetraspanin proteins have been studied individually, tetraspanin proteins and their ..
  35. Lim Y, Cho G, Minarcik J, Golden J. Altered BMP signaling disrupts chick diencephalic development. Mech Dev. 2005;122:603-20 pubmed
    ..In summary, our data indicate that while not necessary, BMP signaling via Bmpr1a and Bmpr1b, is sufficient to modify nuclear organization in the chick diencephalon. ..
  36. Toren A, Bielorai B, Jacob Hirsch J, Fisher T, Kreiser D, Moran O, et al. CD133-positive hematopoietic stem cell "stemness" genes contain many genes mutated or abnormally expressed in leukemia. Stem Cells. 2005;23:1142-53 pubmed
    ..stemness genes, we identified several groups of genes that have an important role in hematopoiesis: growth factor receptors, transcription factors, genes that have an important role in development, and genes involved in cell ..
  37. Zhang J, Wang Y, Chu Y, Su L, Gong Y, Zhang R, et al. Agrin is involved in lymphocytes activation that is mediated by alpha-dystroglycan. FASEB J. 2006;20:50-8 pubmed
    ..Taken together, these findings strongly indicate that agrin and alpha-dystroglycan mediate lymphocyte activation. Furthermore, agrin-involved lymphocyte activation is mediated by alpha-dystroglycan. ..
  38. Matsumoto K, Nakamura T. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int J Cancer. 2006;119:477-83 pubmed
    ..In normal tissues, the HGF-Met axis plays diverse roles in organogenesis and in wound healing. The simile that "cancer is a never-healing wound" appears to be pertinent here. ..
  39. Silvestri A, Fraser H. Oestrogen and progesterone receptors in the marmoset endometrium: changes during the ovulatory cycle, early pregnancy and after inhibition of vascular endothelial growth factor, GnRH or ovariectomy. Reproduction. 2007;134:341-53 pubmed
    ..It is concluded that the steroid receptor profile in the marmoset endometrium is generally similar to the human and should provide a useful model for studies on hormonal manipulation of the endometrium. ..
  40. Heath E, Carducci M. New targets in the management of prostate cancer. Hematol Oncol Clin North Am. 2006;20:985-99, xi pubmed
    ..Efficient trial design, appropriate selection of correlative markers,and close toxicity monitoring will help improve our ability to identify promising novel agents. ..
  41. Jackson P, Boccuto L, Skinner C, Collins J, Neri G, Gurrieri F, et al. Further evidence that the rs1858830 C variant in the promoter region of the MET gene is associated with autistic disorder. Autism Res. 2009;2:232-6 pubmed publisher
    ..20; 95% CI=0.56-2.56; chi(2)=0.2, df=1, P=0.64). This study is the third independent study to find the rs1858830 C variant in the MET gene promoter to be associated with autism. ..
  42. Sabnis G, Jelovac D, Long B, Brodie A. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res. 2005;65:3903-10 pubmed
    ..Cross-talk between ER and growth factor signaling was evident as inhibition of these pathways could restore estrogen responsiveness to these cells. ..
  43. Dupont S, Zacchigna L, Cordenonsi M, Soligo S, Adorno M, Rugge M, et al. Germ-layer specification and control of cell growth by Ectodermin, a Smad4 ubiquitin ligase. Cell. 2005;121:87-99 pubmed
    ..We propose that Ectodermin is a key switch in the control of TGF-beta gene responses during early embryonic development and cell proliferation. ..
  44. Naz R, Sellamuthu R. Receptors in spermatozoa: are they real?. J Androl. 2006;27:627-36 pubmed
  45. Krzystek Korpacka M, Matusiewicz M, Banas T. [Structure and function of midkine, a novel heparin-binding growth factor]. Postepy Hig Med Dosw (Online). 2006;60:591-601 pubmed
  46. Agarwal S, Zerillo C, Kolmakova J, Christensen J, Harris L, Rimm D, et al. Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells. Br J Cancer. 2009;100:941-9 pubmed publisher
    ..Phosphoproteomic analysis by RTK capture arrays may be a valuable tool for identifying the subset of tumours with functional receptor activation, regardless of mechanism. ..
  47. Schlondorff D, Banas B. The mesangial cell revisited: no cell is an island. J Am Soc Nephrol. 2009;20:1179-87 pubmed publisher
    ..Another potentially fruitful area of future research is the role of mesangial cells as local modulators of innate and adaptive immune responses. Thus, mesangial cell research still holds much promise. ..
  48. Ribatti D. Transgenic mouse models of angiogenesis and lymphangiogenesis. Int Rev Cell Mol Biol. 2008;266:1-35 pubmed publisher
  49. Picciotti P, Fetoni A, Paludetti G, Wolf F, Torsello A, Troiani D, et al. Vascular endothelial growth factor (VEGF) expression in noise-induced hearing loss. Hear Res. 2006;214:76-83 pubmed
    ..Our data suggest a role for VEGF in the regulation of the vascular network in the inner ear after acoustic trauma and during auditory recovery, with potentially important clinical and therapeutic implications. ..
  50. Lee W, Choi C, Cha S, Oh H, Kim Y. Role of ERK in hydrogen peroxide-induced cell death of human glioma cells. Neurochem Res. 2005;30:263-70 pubmed
  51. Fredericks D, Smucker J, Petersen E, Bobst J, Gan J, Simon B, et al. Effects of direct current electrical stimulation on gene expression of osteopromotive factors in a posterolateral spinal fusion model. Spine (Phila Pa 1976). 2007;32:174-81 pubmed
  52. Cantelmo A, Cammarota R, Noonan D, Focaccetti C, Comoglio P, Prat M, et al. Cell delivery of Met docking site peptides inhibit angiogenesis and vascular tumor growth. Oncogene. 2010;29:5286-98 pubmed publisher
  53. Xu L, Nilsson M, Saintigny P, Cascone T, Herynk M, Du Z, et al. Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene. 2010;29:2616-27 pubmed publisher
    ..These findings establish that, absent MET amplification, EGFR signaling can regulate MET levels through HIF-1alpha and that MET is a key downstream mediator of EGFR-induced invasiveness in EGFR-dependent NSCLC cells. ..